Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EASE-2 phase IIa empagliflozin adjunctive insulin trial in type 1 diabetes
2011-004354-25Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of empagliflozin in diabetes mellitus type 1 (T1D) (4 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Change from baseline in 24-hour urinary glucose excretion after 7 days. Started Sep 2013; status: completed.
02
Drugs
empagliflozin
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on 2011-004354-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004354-25.